Clinical trials: Oxaliplatin
Colorectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin, irinotecan combined with…
- Trial name
- NCT02688023
- Testing
- oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese Academy of Medical Sciences
Gastric Cancer
Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial
The optimal regimen for adjuvant treatment has not been established in GC yet. We plan to compare TS-1, TS-1/oxaliplatin with or without RT in D2 resected gastric cancer.
- Trial name
- ARTIST-II (NCT01761461)
- Testing
- TS-1, oxaliplatin
- Where
- South Korea
- Volunteers
- 547 people
- Sponsor
- Samsung Medical Center
Gastric Cancer
S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients
The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric Adenocarcinoma or Gastroesophageal Junction…
- Trial name
- NCT01824459
- Testing
- S-1, Oxaliplatin, Cisplatin
- Where
- China
- Volunteers
- 576 people
- Sponsor
- Sun Yat-sen University
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
- Trial name
- EOXP (NCT00667420)
- Testing
- panitumumab, epirubicin, oxaliplatin, xeloda
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Biliary Cancer, Bile Duct Cancer
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Background: Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with advanced BTC have few treatment options, and their survival rates are very low.
- Conditions
- Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
- Trial name
- NCT05849480
- Testing
- oxaliplatin, capecitabine, Keytruda
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Neoplasm, Peritoneal Carcinomatosis
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
A randomized controlled two-armed phase III trial for gastric cancer patients with peritoneal dissemination. Randomization between gastrectomy + cytoreductive surgery + HIPEC (experimental arm) and palliative systemic…
- Trial name
- PERISCOPEII (NCT03348150)
- Testing
- Cytoreductive surgery + Gastrecomy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- The Netherlands Cancer Institute
Liver Metastasis
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases.
- Trial name
- NCT01511146
- Testing
- Oxaliplatin, Mitomycin + Gemcitabine
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital at Herlev
Colorectal Cancer
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
The investigators hypothesize that atezolizumab will improve the prognosis of patients with stage III dMMR CRC ineligible for or refusing oxaliplatin-based adjuvant chemotherapy compared to SOC and that these could therefore be…
- Trial name
- ANTONIO (NCT05118724)
- Testing
- Atezolizumab, IMM-101
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- AIO-Studien-gGmbH
Rectal Cancer
Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
RATIONALE: Preoperative 5-Fu based chemoradiation has become standard treatment for stage 2/3 rectal cancer. However whether these patients, especially T3N0-1M0 patients, really need radiation for local control after total…
- Trial name
- FOWARC (NCT01211210)
- Testing
- fluorouracil, fluorouracil, oxaliplatin
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Sun Yat-sen University
Advanced Pancreatic Cancer
Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
The main research objective is to work out the optimal doses of the novel combination of gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic cancer that has progressed during or after…
- Trial name
- RPGOG1 (NCT01048320)
- Testing
- Gemcitabine, Oxaliplatin, Imatinib
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Diffuse Large B-Cell Lymphoma
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
The purpose of this study is to determine the recommended dose of CMC544 administered in combination with rituximab (R-CMC544), and in alternance with rituximab, gemcitabine and oxaliplatin (R-GEMOX) in the first phase of the…
- Trial name
- NCT01562990
- Testing
- Rituximab, CMC544, Gemcitabine and Oxaliplatine
- Where
- 11 sites in Belgium, France
- Volunteers
- 11 people
- Sponsor
- The Lymphoma Academic Research Organisation
Colorectal Cancer
Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
Primary objective : To compare the combination of S-1 and oxaliplatin(SOX) to the combination of capecitabine and oxaliplatin(COX) therapy for advanced or metastatic colorectal carcinoma. Secondary objectives : 1.
- Trial name
- NCT00677443
- Testing
- S-1 & Oxaliplatin, Capecitabine & Oxaliplatin
- Where
- 11 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Samsung Medical Center
Liver Cancer
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, doxorubicin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00471484
- Testing
- recombinant interferon alfa-2b, doxorubicin hydrochloride, fluorouracil
- Where
- Singapore
- Volunteers
- 54 people
- Sponsor
- National Cancer Centre, Singapore
Colorectal Cancer Stage IV
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
The purpose of this work is to verify prospectively what the rate of response after triple chemotherapy with mFOLFIRINOX in patients in IV stage of Colorectal Cancer who have already failed after at least two lines of dual…
- Trial name
- Re-Play (NCT05354817)
- Testing
- mFOLFIRINOX
- Where
- Brazil
- Volunteers
- 25 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Gastric Cancer, GastroEsophageal Cancer
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by SHR-1210 plus apatinib versus capecitabine and oxaliplatin as…
- Trial name
- NCT03813784
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 885 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy
- Trial name
- NCT04338438
- Testing
- Apatinib Mesylate tablets combined with S-1 capsules
- Volunteers
- 37 people
- Sponsor
- Beijing Friendship Hospital
Carcinoma, Hepatocellular
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Primary objective: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV Secondary objective: To evaluate time to progression, 6month…
- Trial name
- NCT00559455
- Testing
- Oxaliplatin, Fluorouracil, Leucovorin
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sanofi
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Rectal Cancer
Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Phase II pilot study of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy for patients with locally advanced rectal carcinoma
- Trial name
- NCT01434147
- Testing
- preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
- Where
- 7 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Digestive Cancer
A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan
This study is to determine the Maximal Tolerated Dose (MTD), the Dose Limitant Toxicities (DLTs) and the safety profile of S-1 combined with fixed doses of Irinotecan (SIRI schedule) and fixed doses of Irinotecan and Oxaliplatin…
- Trial name
- SIRINOX (NCT02387138)
- Testing
- S-1, Irinotecan, Oxaliplatin
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle